骨髓间充质干细胞移植（MSCs）是治疗肝损伤最具潜力的方法之一。但是，移植MSCs在受体肝脏生存率低、存活时间短等关键问题影响了其对损伤肝脏的治疗效果。有研究提示受体NK细胞和T细胞介导的免疫排斥反应与以上现象有密切相关性。本课题拟采用分别负载CMV和白蛋白（Alb）启动子报告基因的同种异体MSCs，对肝损伤模型小鼠进行肝内移植，分别采用anti-asialo GM1清除宿主体内NK细胞和Tacrolimus抑制T细胞介导的免疫排斥反应，通过生物发光成像活体动态示踪MSCs存活、增殖及向肝细胞的分化情况；同时检测肝脏和脾脏淋巴细胞的数量、功能，探讨淋巴细胞介导的免疫排斥反应对移植MSCs的存活、增殖和分化的作用及其机制。本课题的预期结果将有助于优化MSCs移植治疗方案，推动MSCs移植的临床应用。

Transplantation of bone marrow-derived mesenchymal stem cells(MSCs) has been suggested as a potential therapeutic approach for liver injury. However, the transplanted MSCs have low survival rate and short survival time in the host liver, which decreases the therapeutic efficiency to the injured liver. Some researchs hinted that NK cells and T cells mediated immune rejection may be related to the above phenomenan. In this project, allogenic MSCs will be labeled with CMV or Albumin (Alb) promoter-driven reporter genes and transplanted to the mice of liver injury model. Anti-asialo GM1 which can reduce the activity of NK cells and Tacrolimus which can supress T cell activation will be administrated to the mice. The survival, proliferation and hepatocyte differentiation of transplanted MSCs will be dynamically monitored through in vivo bioluminescent imaging.At the same time,the proportion and function of NK cells and T cells in host liver and spleen will be detected. Through in vivo and in vitro experiments, we intend to elucidate the action of immune rejection to the survival, proliferation and differentiation of transplanted MSCs and the related mechanism. The expected results of this project will enhance the treatment scheme optimination of MSCs transplantation and improve progress of its clinical application.